Lilly再出手，5.75億美元收購腫瘤藥企業(yè)AurKa Pharma，獲得Aurora激酶抑制劑AK-01

2018-05-15 13:30:46


#LLY


正在布局抗腫瘤藥產(chǎn)品線的Lilly繼續(xù)發(fā)力

繼收購Armo BioSciences之后

今日又宣布收購AurKa Pharma

1.1億美元首付款

外加4.65億美元的里程碑款項

以及一定的銷售額分成

AurKa Pharma

2016年成立于加拿大蒙特利爾

TVM Capital Life Science Venture Capital第十二個投資項目

成立之初

正是旨在開發(fā)Lilly旗下抗腫瘤活性化合物

也是此次看中的為Aurora激酶抑制劑AK-01

目前處于臨床I期研究中


Aurora激酶主要參與調(diào)節(jié)中心體和微管的功能

以保證染色體的精確分離和胞質(zhì)的有效分離

通常都在G2-M期達到高峰

調(diào)節(jié)著細胞周期中G2-M轉(zhuǎn)換

是調(diào)節(jié)M期進展的關(guān)鍵因子



Aurora激酶由3個亞群組組成

Aurora-A、Aurora-B和Aurora-C

此時的過表達則導致遺傳的不穩(wěn)定性

造成細胞多倍體誘發(fā)惡性腫瘤

AurKa旗下的AK-01對Aurora-A有高度選擇性

臨床I期試驗也證明了潛在的臨床收益

后續(xù)臨床將繼續(xù)評估臨床收益與風險的結(jié)果


Darren Carroll
Senior vice president of corporate business development at Lilly
“

The acquisition of AurKa Pharma supports Lilly's external innovation strategy, in which we seek to partner with leading life science venture capital firms in order to identify, support and access promising innovation in areas of unmet medical need. We are excited with the value TVM created for this compound through its early-Phase studies, and we look forward to more opportunities in the future.

”


Luc Marengere, Ph.D.
Managing Partner at TVM Capital Life Science
“

Through the unique healthcare venture capital model pioneered by TVM Capital Life Science, companies such as AurKa have been established to more quickly and efficiently bring promising compounds to clinical proof-of-concept. We are pleased that the scientific advances made by AurKa could contribute to the development of AK-01 and hopefully help deliver a potential new medicine for cancer patients.

”




Takeda在2015年終止了Aurora A抑制劑Alisertib

用于復發(fā)或難治性外周T細胞淋巴瘤III期臨床研究

但SCLC二線臨床II期研究還在等待

而AK-01此前的臨床I期研究中

選擇的是小細胞肺癌、乳腺癌和頭頸癌適應(yīng)癥的二線用藥

Lilly這一步棋走的有點意思

當然這個收購之路還將繼續(xù)

4-5筆剛完成2筆